vs
Side-by-side financial comparison of Ares Commercial Real Estate Corp (ACRE) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $13.2M, roughly 1.4× Ares Commercial Real Estate Corp). SCYNEXIS INC runs the higher net margin — 65.7% vs -29.2%, a 95.0% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs -24.5%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs -15.9%).
Ares Commercial Real Estate Corp is a specialty finance company focused on the commercial real estate sector. It offers a full suite of customized financing solutions including senior mortgage loans, subordinated debt and preferred equity, primarily serving middle-market commercial property owners and operators across the United States.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
ACRE vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.2M | $18.6M |
| Net Profit | $-3.9M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | -29.2% | 56.3% |
| Net Margin | -29.2% | 65.7% |
| Revenue YoY | -24.5% | 1808.5% |
| Net Profit YoY | 63.8% | 376.5% |
| EPS (diluted) | — | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.2M | $18.6M | ||
| Q3 25 | $14.1M | $334.0K | ||
| Q2 25 | $12.6M | $1.4M | ||
| Q1 25 | $14.9M | $257.0K | ||
| Q4 24 | $17.5M | $977.0K | ||
| Q3 24 | $16.7M | $660.0K | ||
| Q2 24 | $16.8M | $736.0K | ||
| Q1 24 | $18.7M | $1.4M |
| Q4 25 | $-3.9M | $12.3M | ||
| Q3 25 | $4.7M | $-8.6M | ||
| Q2 25 | $-11.0M | $-6.9M | ||
| Q1 25 | $9.3M | $-5.4M | ||
| Q4 24 | $-10.7M | — | ||
| Q3 24 | $-5.9M | $-2.8M | ||
| Q2 24 | $-6.1M | $-14.5M | ||
| Q1 24 | $-12.3M | $411.0K |
| Q4 25 | -29.2% | 56.3% | ||
| Q3 25 | 33.0% | -2516.5% | ||
| Q2 25 | -87.8% | -701.0% | ||
| Q1 25 | 64.4% | -3350.2% | ||
| Q4 24 | -61.0% | — | ||
| Q3 24 | -35.3% | -1563.6% | ||
| Q2 24 | -36.5% | -1255.0% | ||
| Q1 24 | -65.9% | -692.5% |
| Q4 25 | -29.2% | 65.7% | ||
| Q3 25 | 33.0% | -2572.2% | ||
| Q2 25 | -87.8% | -504.8% | ||
| Q1 25 | 62.5% | -2097.7% | ||
| Q4 24 | -60.9% | — | ||
| Q3 24 | -35.3% | -425.5% | ||
| Q2 24 | -36.5% | -1964.4% | ||
| Q1 24 | -65.9% | 29.9% |
| Q4 25 | — | $0.25 | ||
| Q3 25 | — | $-0.17 | ||
| Q2 25 | — | $-0.14 | ||
| Q1 25 | — | $-0.11 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.06 | ||
| Q2 24 | — | $-0.30 | ||
| Q1 24 | — | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $29.3M | $40.0M |
| Total DebtLower is stronger | $948.2M | — |
| Stockholders' EquityBook value | $509.6M | $49.4M |
| Total Assets | $1.6B | $59.0M |
| Debt / EquityLower = less leverage | 1.86× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $29.3M | $40.0M | ||
| Q3 25 | $84.9M | $37.9M | ||
| Q2 25 | $90.0M | $44.8M | ||
| Q1 25 | $125.5M | $40.6M | ||
| Q4 24 | $63.8M | $59.3M | ||
| Q3 24 | $68.9M | $68.8M | ||
| Q2 24 | $70.6M | $73.0M | ||
| Q1 24 | $99.5M | $80.2M |
| Q4 25 | $948.2M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $718.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $509.6M | $49.4M | ||
| Q3 25 | $521.0M | $36.4M | ||
| Q2 25 | $523.7M | $44.5M | ||
| Q1 25 | $542.1M | $50.5M | ||
| Q4 24 | $540.1M | $55.1M | ||
| Q3 24 | $563.8M | $58.5M | ||
| Q2 24 | $582.3M | $60.4M | ||
| Q1 24 | $601.1M | $74.1M |
| Q4 25 | $1.6B | $59.0M | ||
| Q3 25 | $1.4B | $51.1M | ||
| Q2 25 | $1.4B | $60.7M | ||
| Q1 25 | $1.5B | $67.9M | ||
| Q4 24 | $1.8B | $90.6M | ||
| Q3 24 | $1.9B | $99.0M | ||
| Q2 24 | $2.1B | $107.8M | ||
| Q1 24 | $2.1B | $118.3M |
| Q4 25 | 1.86× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.33× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $21.4M | $18.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $21.4M | $18.4M | ||
| Q3 25 | $3.8M | $-8.7M | ||
| Q2 25 | $4.9M | $-7.5M | ||
| Q1 25 | $8.0M | $-7.5M | ||
| Q4 24 | $35.5M | $-24.0M | ||
| Q3 24 | $8.4M | $765.0K | ||
| Q2 24 | $8.7M | $-10.9M | ||
| Q1 24 | $11.4M | $-4.0M |
| Q4 25 | — | 1.50× | ||
| Q3 25 | 0.82× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.86× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACRE
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
